MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

Jul 10, 2023

News

MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment
MGI's DNBSEQ-T20*x2 Wins 2023 Globee® Awards for Medical Equipment

MGI: A World-Leading Innovator in Gene Sequencing and Life Science

MGI, a world-leading innovator in gene sequencing and life science, is thrilled to announce that its DNBSEQ-T20×2 ("T20") gene sequencing platform has been awarded the prestigious Globee® for Medical Equipment in the 15th Annual 2023 Golden Bridge Business and Innovation Awards®. This award is a testament to MGI's commitment to pushing the boundaries of technology advancements and making significant contributions to the genetic industry.

The Golden Bridge Awards: Recognizing Visionaries and Innovators

The Golden Bridge Awards, a global recognition platform for business practices, is renowned for organizing world-class business awards programs and business ranking lists. The awards honor visionaries, innovators, and leaders who have made significant contributions in various domains of business and technology. The Golden Bridge Awards are a symbol of excellence and recognition for those who are reshaping their respective industries through innovative business practices.

MGI's Cutting-Edge Technology Advancements and Contributions

The Golden Bridge Awards carefully select experienced judges from diverse industries and backgrounds to conduct a comprehensive evaluation of the entries. This ensures that the award truly reflects the outstanding achievements and contributions of the winners in their respective fields. Among the other award winners are Amazon, IBM, and Meta, which have also been honored for their innovative business practices. This is the second time MGI has won the Golden Bridge Awards, symbolizing the global recognition of MGI's cutting-edge technology advancements and significant contributions to the life science industry.

MGI's T20*: An Ultra-High-Throughput Gene Sequencer

Launched in February 2023, MGI's T20* gene sequencer is a groundbreaking innovation in the field of gene sequencing. It is designed to improve the efficiency of our sequencing platform for even faster and higher throughput sequencing. This makes sequencing-based health monitoring and disease prevention at the molecular level affordable for all. The T20* is a testament to MGI's commitment to leading innovation in the genetic industry and reshaping healthcare outcomes.

T20*'s Impact on the Genetic Industry and Healthcare

T20* successfully reduces the unit cost of genome sequencing to sub $100, becoming an important driving force for the expansion of the global genetic industry. This will accelerate the progress of human genome understanding and medical applications, and fundamentally reshape the industry ecology. The T20* is not just a gene sequencer; it is a revolutionary tool that is making genome sequencing accessible and affordable, thereby promoting precision medicine and disease prevention.

MGI's Commitment to Leading Life Science Innovation

"We are honored to receive this prestigious award for two consecutive years," expressed Duncan Yu, President at MGI, "The victory of Globee® Awards further strengthens our commitment to providing innovative solutions that enable scientists to advance research and improve healthcare outcomes. And we will continue to innovate and push boundaries of what is possible in this field."

MGI is dedicated to breaking the boundary of production capacity, aiming to provide powerful sequencers with ultra-high throughput, ultra-low cost, and intelligent integration for global users. In the future, MGI will continue to work closely with global partners to promote the healthy development of the life science industry based on its unique DNBSEQ sequencing technology, ultra-high-throughput sequencing platform, and adherence to the concept of leading life science innovation. MGI is not just a company; it is a global leader in life science innovation, reshaping the future of healthcare and the genetic industry.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

Globee Awards

Life Science Research

High-Throughput Sequencing

MGI-Tech Innovation

Golden Bridge Awards

Share

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer
Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

Mar 4, 2024

Elevating Precision Health: MGI Tech and Eurofins Genomics Unite with DNBSEQ-T20×2 Sequencer

MGI Tech has joined forces with Eurofins Genomics Europe Genotyping A/S, marking a pivotal moment in the advancement of large-scale genomic projects. This partnership heralds the first corporate order of the DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in Europe.

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding
Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Nov 10, 2023

Latvia MGI Tech SIA Advances DNA Methylation Research with Significant European Funding

Latvia MGI Tech SIA advances DNA methylation research with significant European funding, achieving groundbreaking progress in biotechnology and innovation.

Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow
Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

Jun 14, 2023

Unveiling MGI's Groundbreaking Innovations at the ESHG Conference in Glasgow

Discover the groundbreaking partnerships and innovations unveiled by MGI Tech Co., Ltd. at the ESHG Conference in Glasgow. Learn about MGI's strategic collaborations in the European life sciences market, their advancements in sequencing and automation technologies, and their commitment to revolutionizing genomics research. This post also highlights MGI's strategic partnership with Alithea Genomics, aiming to innovate in RNA sequencing.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.